Condition: Non-small Cell Lung Cancer · Lung Cancer · Sponsor: Daiichi Sankyo
This study will compare Valemetostat Tosylate Plus Pembrolizumab vs Pembrolizumab Alone in First-line NSCLC Without Actionable Genomic Alterations
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| University of California San Diego (Ucsd)-Moores Cancer Center | La Jolla, California, United States | — |
| California Research Institute | Los Angeles, California, United States | — |
| Valkyrie Clinical Trials | Los Angeles, California, United States | — |
| Mayo Clinic Hospital | Jacksonville, Florida, United States | — |
| BRCR Global | Plantation, Florida, United States | — |
| University of Kentucky Medical Center | Lexington, Kentucky, United States | — |
| Pikeville Medical Center | Pikeville, Kentucky, United States | — |
| Mayo Clinic - Rochester | Rochester, Minnesota, United States | — |
| Columbia University Irving Medical Center | New York, New York, United States | — |
| Thomas Jefferson University, Sidney Kimmel Cancer Center | Philadelphia, Pennsylvania, United States | — |
| Virginia Cancer Specialist | Fairfax, Virginia, United States | — |
| Hospital Italiano de Buenos Aires | Buenos Aires, Argentina | — |
+ 23 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06644768